1991
L-Deprenyl (Selegiline) Added to Sinemet CR in the Management of Parkinson's Disease Patients With Motor Response Fluctuations.
Cedarbaum JM, Toy LH, Green-Parsons A. L-Deprenyl (Selegiline) Added to Sinemet CR in the Management of Parkinson's Disease Patients With Motor Response Fluctuations. Clinical Neuropharmacology 1991, 14: 228. PMID: 1906374, DOI: 10.1097/00002826-199106000-00005.Peer-Reviewed Original ResearchConceptsSinemet CRParkinson's diseaseResponse fluctuationsDisease patientsL-deprenylMean interdose intervalTherapeutic response fluctuationsAdvanced Parkinson's diseaseMotor response fluctuationsParkinson's disease patientsLevodopa intakeMotor fluctuationsInterdose intervalTreatment regimensPatientsSignificant reductionDeprenylDiseaseRegimensDyskinesiaImproved control
1990
Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements.
Cedarbaum J, Silvestri M, Kutt H. Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements. Neurology 1990, 40: 995-7. PMID: 2345621, DOI: 10.1212/wnl.40.6.995.Peer-Reviewed Original ResearchConceptsInterrupted infusionTherapeutic response fluctuationsStriatal dopamine receptorsContinuous enteral infusionLevodopa dose requirementEnteral administrationEnteral infusionContinuous infusionDopamine receptorsInfusion rateParkinson's diseaseDose requirementsInfusionResponse fluctuationsMotor performanceLevodopaDiseasePatientsAdministrationReceptorsL-Deprenyl, Levodopa Pharmacokinetics, and Response Fluctuations in Parkinson's Disease.
Cedarbaum JM, Silvestri M, Clark M, Harts A, Kutt H. L-Deprenyl, Levodopa Pharmacokinetics, and Response Fluctuations in Parkinson's Disease. Clinical Neuropharmacology 1990, 13: 29. PMID: 2106391, DOI: 10.1097/00002826-199002000-00003.Peer-Reviewed Original ResearchConceptsParkinson's diseaseResponse fluctuationsL-deprenylTherapeutic response fluctuationsTotal levodopa doseOpen-label trialPlasma levodopa concentrationsPlasma levodopa levelsEffect of deprenylWeeks of treatmentDaily levodopaLevodopa doseLevodopa pharmacokineticsPeripheral pharmacokineticsAction of MAOLevodopa treatmentMost patientsDOPAC levelsLevodopa levelsDopaminergic activityLevodopa concentrationsMild endDose failureTherapeutic actionPatients
1987
Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
Cedarbaum J, Breck L, Kutt H, McDowell F. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease. Neurology 1987, 37: 1607-12. PMID: 3658164, DOI: 10.1212/wnl.37.10.1607-a.Peer-Reviewed Original ResearchConceptsSinemet CR4Interdose intervalParkinson's diseaseResponse fluctuationsTherapeutic response fluctuationsOpen-label trialPlasma levodopa levelsSlow-release preparationAntiparkinsonian effectsStandard levodopaLevodopa dosesLevodopa preparationsLevodopa levelsDaily dosesRelease preparationDiseaseLevodopaDosesProlongationTreatmentOverall benefitSinemetPatientsSlight reductionClinical Pharmacokinetics of Anti-Parkinsonian Drugs
Cedarbaum J. Clinical Pharmacokinetics of Anti-Parkinsonian Drugs. Clinical Pharmacokinetics 1987, 13: 141-178. PMID: 3311529, DOI: 10.2165/00003088-198713030-00002.Peer-Reviewed Original ResearchConceptsAnti-parkinsonian agentsAnti-parkinsonian drugsClinical PharmacokineticsParkinson's diseaseDirect acting dopamine receptor agonistsLarge neutral amino acidsResponse fluctuationsAnti-parkinsonian actionLittle pharmacokinetic dataPharmacodynamics of levodopaTherapeutic response fluctuationsPlasma levodopa concentrationsDopamine receptor agonistsPotential drug toxicityClass of drugsMechanism of actionParkinsonian populationRenal functionPharmacokinetic considerationsUnchanged drugBrain uptakeReceptor agonistRenal excretionShort eliminationLevodopa concentrations